Evidence map›Paper›PMID 32026490›Full record

Trial reportJournal of clinical pharmacology2020

A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver.

Yuji Kumagai, Tomoe Fujita, Mika Maeda, Yoshinobu Sasaki, Makoto Nagaoka, Jinhong Huang, Toru Takenaka, Masaki Kawai

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuji KumagaiKitasato University Hospital, Kanagawa, Japan.
Tomoe FujitaKitasato University Hospital, Kanagawa, Japan.
Mika MaedaKitasato University Hospital, Kanagawa, Japan.
Yoshinobu SasakiKitasato University Hospital, Kanagawa, Japan.
Makoto NagaokaTaiho Pharmaceutical Co., Ltd., Tokyo, Japan.
Jinhong HuangTaiho Pharmaceutical Co., Ltd., Tokyo, Japan.
Toru TakenakaTaiho Pharmaceutical Co., Ltd., Tokyo, Japan.
Masaki KawaiTaiho Pharmaceutical Co., Ltd., Tokyo, Japan.ORCID 0000-0001-8620-7317
Kitasato University Hospital · JPTaiho Pharmaceutical (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TAS-303 (4-piperidinyl 2,2-diphenyl-2-[propoxy-1,1,2,2,3,3,3-d

Indexed as

Administration, IntravenousAdministration, OralAdrenergic Uptake InhibitorsAdultAnesthetics, IntravenousAnticholesteremic AgentsArea Under CurveComputer SimulationCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsDrug InteractionsHealthy VolunteersHumansIntestine, SmallLiverMaleAdrenergic Uptake InhibitorsAnesthetics, IntravenousAnticholesteremic AgentsCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsMidazolamSimvastatinclinical pharmacologyclinical trials (CTRs)drug-drug interactionsmodel & simulationPBPKpharmaceutical R & D (PRD)

Identifiers

PMID32026490
PMCPMC7318569
OpenAlexW3005176075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.